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Summary
Background: Risk indices have been developed to
identify women at risk of low bone mineral density
(BMD) who should undergo BMD testing.
Aim: To compare the performance of four risk
indices in White ambulatory women in Belgium.
Design: Epidemiological cross-sectional study.
Methods: Records were analysed for 4035 post-
menopausal White women without Paget’s disease
or advanced osteoarthritis, seen at an out-patient
osteoporosis centre between January 1996 and
September 1999. Osteoporosis risk index scores
were compared to bone density T-scores. The ability
of each risk index to identify women with low BMD
(T-score <2.0) or osteoporosis (T <2.5) was
evaluated.
Results: Using an Osteoporosis Self-Assessment
Tool (OST) score <2 to recommend DXA referral,
sensitivity ranged from 85% at the lumbar spine to
97% at the total hip to detect BMD T-scores of
2.5, and specificity ranged from 34% at the total
hip to 37% at the femoral neck and lumbar spine.
The negative predictive value was high at all
skeletal sites (89–99%), demonstrating the useful-
ness of the OST to identify patients who have
normal BMD and should not receive DXA testing.
All risk indices performed similarly, although the
OST had somewhat better sensitivity and somewhat
lower specificity than the other indices at the cut-
offs evaluated. Among the 11–12% of women who
were classified as highest risk using OST or the
Osteoporosis Index of Risk (OSIRIS), 81–85% had
low bone mass and 68–74% had osteoporosis.
Discussion: The performance of these risk indices
among women in Belgium was similar to that
reported earlier for other samples in Asian countries,
the US, and the Netherlands. The OST and other risk
indices are effective and efficient tools to help target
high-risk women for DXA testing.
Introduction
Osteoporosis is a major public health concern
worldwide. The medical, social and psychological
consequences can severely impact the health-
related quality of life of patients with fractures, and
are life-threatening for some patients.1–3 Osteoporo-
sis is ‘a systemic skeletal disorder characterized by
low bone mass and micro-architectural deteriora-
tion of bone tissue, with a consequent increase in
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bone fragility and susceptibility to fracture.‘4 This
definition clearly introduces the association
between low bone mass and increased fracture
risk, allowing for an operational definition of
osteoporosis based on bone mineral density
(BMD).5
Osteoporosis is common among postmenopausal
women, but is often asymptomatic. It is widely
accepted that osteoporosis can be diagnosed using
BMD measurements, generally made at the hip or
spine using dual X-ray absorptiometry (DXA). Some
researchers have recommended that BMD measure-
ments be targeted to subjects with risk factors
for osteoporosis, because of limited availability of
BMD technology in some communities, and cost
considerations.5,6
Comprehensive epidemiological studies have
identified clinical risk factors for osteoporosis,
and these risk factors have been used to develop
risk assessment indices.7–15 The purpose of the
risk assessment indices is not to diagnose osteo-
porosis or low BMD, but to identify women who
are more likely to have low BMD. These patients
can then be referred for BMD measurements.
Such indices, while not identifying all cases of
osteoporosis, increase the efficiency of BMD
measurement by focusing on subjects who are at
increased risk.
The Osteoporosis Self-assessment Tool (OST)14 is
based simply on age and weight. It was developed
and validated in several studies in Asian and White
populations,14 and was compared to other risk
indices in large samples of postmenopausal
women.16 The authors reported that OST predicted
low BMD as well as other indices did, and they
considered OST to be the easiest to use in clinical
practice. Other risk tools are also based on age and
weight, in combination with up to four additional
risk factors; these include the Osteoporosis Risk
Assessment Instrument (ORAI),15 the Simple Calcu-
lated Osteoporosis Risk Estimation (SCORE),10 and
the Osteoporosis Index of Risk (OSIRIS).17 These
four risk assessment tools have been proposed
for increasing awareness of osteoporosis and for
encouraging more efficient use of BMD measure-
ments in patients who are likely to have low bone
mass, especially in asymptomatic postmenopausal
women.
Our goals were to assess the validity of OST in
a population of 4035 White women from
Belgium, and to compare the performance of the
four tools—OST, ORAI, SCORE and OSIRIS—in
identifying women at risk of low BMD and who
could benefit from definitive osteoporosis evalua-
tion using DXA.
Methods
We analysed a database that was previously used
to assess the discriminatory performance of
SCORE.18 It included medical data on patients
either consulting spontaneously or referred for a
BMD measurement between January 1996 and
September 1999 to an out-patient osteoporosis
center located at the University of Lie`ge in Belgium.
Referral was based on diagnostic judgment of the
referring physician. Informed consent was obtained
from all eligible study participants. Patients with
Paget’s disease and advanced osteoarthritis were
excluded. The research protocol was reviewed and
approved by the institutional review board of the
University of Lie`ge.
The following outcomes were recorded for 4035
postmenopausal women: BMD, age, weight, history
of rheumatoid arthritis, non-traumatic fracture his-
tory after age 45 years, and history of oestrogen use.
BMD measurements, using DXA technology (Holo-
gic QDR2000), were obtained from the hip (both
total and femoral neck) and lumbar spine (L2–L4).
BMD values, expressed in g/cm2, were converted
into T scores, expressed in standard deviations
(SDs), using QDR reference values specifically
established for the population of Lie`ge.19,20
We used the WHO classification range to cate-
gorize subjects as normal (T >1), osteopenic
(2.5 < T1), or osteoporotic (T2.5). A sub-
category was defined as ‘low BMD’, for all subjects
with T<2.0, to allow comparison to published
results for some risk indices that were based on
this cutoff.10,11 Further, this cutoff is widely used in
many communities to detect pre-osteoporotic
patients.24
The BMD cut-off values for osteopenia and
osteoporosis at the lumbar spine, total hip, and
femoral neck sites in our sample were 1.065
and 0.840; 0.790 and 0.640; and 0.750 and
0.600 g/cm2, respectively. Weight was recorded in
kg in our medical records, so this factor was
converted into pounds by using a multiplier of
2.205 for use in calculating risk indices such as
SCORE.
The OST, ORAI, SCORE, and OSIRIS indices were
then derived according to the algorithms suggested
by their developers (Table 1). The following
dichotomous cutoffs for DXA referral were used:
< 2 for OST, > 7 for SCORE, > 8 for ORAI and < 1 for
OSIRIS. Also, three risk categories were used for
each index, according to their developer’s recom-
mendations and the validation of some indices in
American and European populations.17 Prevalence
of osteoporosis in each of these three categories
were determined using the WHO criteria.
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Prevalence is easier for many clinicians to under-
stand and use than statistical measures of perfor-
mance such as sensitivity and specificity.
Basic demographic data were tabulated to allow
comparison of our study population to that from the
other recent studies by Koh et al.14 and Geusens
et al.16 involving OST. Receiver operating charac-
teristic (ROC) analyses were performed to evaluate
the discriminatory performances of OST, ORAI,
SCORE, and OSIRIS, and the area under the curve
(AUC) was computed for each. To assess the internal
validity of the indices, sensitivity was defined as
the proportion of the population with low BMD
correctly classified by the risk index (true positive
fraction) and specificity was defined as the pro-
portion with normal BMD correctly identified by
the risk index (true negative fraction). ROC curves
provided a graphical representation of the overall
accuracy of a test by plotting sensitivity against
(1–specificity) for all thresholds, while the AUC
quantified the accuracy of the test.
We also calculated the positive predictive value
(PPV) and negative predictive value (NPV) to
evaluate the external validity of each tool. The
PPV and NPV represent the proportion of women
who tested positive or negative (as classified by
the four tools) and who truly had, or did not have,
BMD below the T-score threshold being tested,
respectively.
We evaluated OST, ORAI, SCORE, and OSIRIS at
the BMD T-score thresholds of 2.5 and 2.0, to
assess the performance of those indices in predicting
osteoporosis and low bone mass, respectively. The
ability of the tools to detect different thresholds of
low BMD was also evaluated for various anatomical
sites (total hip, femoral neck, L2–L4) of densitometry
measurement.
Statistical analysis used Statistica 6.0 software
(Statsoft, France).
Results
The mean age of the women in our sample was 61.5
( 8.8) years, ranging from 45 to 96 years. Table 2
shows their basic demographic data as compared to
cohorts studied by Koh et al.14 and Geusens et al.16
The patient population in this study was slightly
younger (61.5 vs. 62.3) than in the study by Koh
et al., while rheumatoid arthritis was less prevalent
in our study sample (< 2%). Only 2.6% reported a
non-traumatic fracture after age 45 at the wrist, rib,
or hip; this was much lower than in the study of
Koh et al.14 The prevalence of osteoporosis at all
sites increased progressively with age (Figure 1). Of
the women in our study, 32% were osteoporotic
(T2.5) at one or more skeletal site, 47% had a
low BMD (T2.0), and 73% were classified as
osteopenic according to the WHO operational
definition. In comparison to the other two cohorts,
the prevalence of low BMD in our population was
higher at the femoral neck.
Table 3 shows the performance of the four risk
indices in identifying patients at various BMD
measurement sites and thresholds (T score values
of 2 and 2.5). Increasing prevalence of osteo-
porosis (T2.5) with ascending risk category
(low, medium, high) was apparent for all four risk
tools. For example, the prevalence of osteoporosis
based on femoral neck BMD was approximately
6%, 22%, and 60% at the low (42% of women),
medium (47% of women), and high (11% of
women) OST risk levels. Compared to measuring
BMD on all women to identify all cases of
osteoporosis (or measuring 90% of women at
random to identify 90% of osteoporosis cases), by
using OST or OSIRIS, BMD testing can be targeted
to the 11% of women at highest risk. Of the women
in our study classified as high risk, 85% had low
bone mass and 74% had osteoporosis.
Table 1 Calculation of the evaluated indices
Factor Score
SCORE
Race other than Black þ 5
Rheumatoid arthritis þ 4
Non-traumatic fracture
after age 45 years
þ 4 per fracture,
up to a maximum of 12
Age þ 3 for each decade
Oestrogen therapy þ 1 if never
Weight  1 for each 10 lb (4.5 kg)
ORAI
Age>75 years þ 15
Age 65–74 years þ 9
Age 55–64 years þ 5
Body weight < 60 kg þ 9
Body weight 60–70 kg þ 3
Oestrogen therapy þ 2 if not currently
using oestrogen
OSIRIS
Body weight (kg) þ 0.2 body weight




Oestrogen therapy þ 2
OST
Body weight (kg)
Age (years) 0.2 (body weight age)
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At the considered thresholds, OST, SCORE, ORAI,
and OSIRIS identified respectively, 88%, 86%, 90%,
and 80% of the patients with normal BMD who
subsequently should not have been recommended
for densitometry, since according to their score they
were ‘low risk’.
Using the dichotomous cut-off value of < 2, the
sensitivity of OST in identifying individuals at
increased risk of osteoporosis ranged from 85%
for lumbar spine to 97% at the total hip region, and
was higher across BMD sites than that of the
other indices. The corresponding specificity of
OST ranged from 34% at the total hip to 40% at
any given site and was lower across sites than the
other indices (Table 4). At the OST cut-off point of 2,
and using a BMD T-score threshold of 2.5 for any
site, 45% of the subjects were misclassified (most of
these were false positives); the proportion of
misclassified patients for single BMD sites was
60% at the total hip, 52% at the femoral neck,
and 51% at the lumbar spine site.
The AUC was consistently high (0.7) for the
two hip sites, and somewhat lower for the spine
(Table 5), indicating good test performance.
For each combination of BMD measurement and
T-score cutoff, the AUC results were similar for all
four risk tools.
Discussion
Although most physicians and patients are aware of
osteoporosis, it is being diagnosed and appropri-
ately treated in only a small proportion of patients;
this is true even for patients who have already had
fractures. The availability of new pharmacological
treatments for osteoporosis has increased pressure
on public health policy makers to support BMD
measurements for patients considered at high risk.21
Effective treatments reduce fracture risk by 33–
50%.22 Several guidelines have been developed
based upon expert opinion, cost-effectiveness
criteria, systematic reviews, and/or predictive
Table 2 Characteristics of the participants
Characteristic This study Development cohort14 Validation cohort16
n 4035 860 1102
Ethnicity (%) Black 0 Black 0 Black 4.9
White 100 White 0 White 81.8
Asian 0 Asian 88 Asian/Other 13.3
Other 0 Other 12
Mean (SD) age (years) 61.5 (8.8) 62.3 (6.2) 61.3 (9.6)
Mean (SD) weight (kg) 65 (11.9) 57.1 (8.2) 70.5 (15.7)
BMD T Score <2.5 (%) FN 18.8 FN 14 FN 13.7
Hip 9.4 (Netherlands sample)
L2–L4 24.2
Oestrogen use (%)
Ever 50.6 NA 62.1
Current 42.1 18 49.2
Prior fractures (%)
Any 12.2 NA 14
After 45 years 2.6 12
Wrist 1.9 NA 5.2
Spine 4.1 NA 2.7
Hip 0.7 NA 1.5
Other 6.5 NA NA
Rheumatoid arthritis (%) 1.2 9 5
FN, femoral neck; L2–L4, lumbar spine L2 to L4.
Figure 1. Prevalence of osteoporosis (T score <2.5) by
age and measurement site.
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models. The US Preventive Service Task Force,23 the
National Osteoporosis Foundation,24 and the North
American Menopause Society25 proposed that all
women aged 65 and older should have BMD
measurements. On the other hand, the National
Institute of Health,26 the WHO Task Force for
Osteoporosis,27 the Canadian Multicentre Osteo-
porosis Study Group15, and the International Osteo-
porosis Foundation10 recommended selecting
patients for BMD measurements based on particular
risk factors.
In our study involving White women aged 45
years and more, the OST successfully identified
most women with osteoporosis and low BMD who
should undergo DXA testing. The OST, based only
on age and weight, performed as well as the more
complex risk assessment indices (SCORE, ORAI,
and OSIRIS) in identifying women at low risk of
osteoporosis who would not need DXA testing.
Avoiding unnecessary testing among low risk
patients can substantially reduce cost for the
community and the patient (DXA is not reimbursed
in some countries). For example, in this sample of
Belgian women, 42% of the women were classified
as low risk using OST, and thus would not need
to be referred to DXA testing. Of these, only 6%
actually had osteoporosis based upon femoral neck
BMD. At the same time, using OST to select the
58% of women at risk for BMD measurements,
90.4% (17/18.8) of all women with osteoporosis at
the femoral neck level would be identified, and only
9.6% would be missed. In contrast, if a random 58%
sample of women had BMD measurements without
using OST, 58% of all low BMD and OP cases
would be identified and 42% would be missed.
On the basis of DXA measurements, of the 4035
subjects who were scanned, 758 (18.8%) had low
BMD at the femoral neck level. Using OST, only
2340 scans (58% of 4035) would have been
performed to detect 685 subjects (30%) with low
BMD at that level, or 1426 subjects (61%) with
low BMD at any site.
Although some women who do not have low
BMD were classified as increased risk (false
positives) and would be referred for testing, some
of these women would have undergone testing
anyway if OST were not used. Among these women,
treatment for low BMD would only be initiated
upon confirmation by DXA—a safe, non-invasive
diagnostic procedure. Thus, a risk assessment tool
such as OST that is free and has no associated harm
does not need to have both high sensitivity and high
specificity. There is no risk of harm to the patient
from unnecessary treatment or invasive diagnostic
testing in case of a false-positive result from OST.
We found the performance of OST in this sample
to be similar to that reported among Asian,14
American and European women of various ethnic
backgrounds,16 despite differences in the reference
databases used for T score calculations.28 We used
Table 3 Prevalence of low BMD and osteoporosis by BMD measurement site and risk category


















>1 (low risk) 42% 1.4% 6% 12.6% 16.1% 4.1% 11.9% 24.3% 28.7%
 3 to 1 (moderate risk) 47% 10.6% 22.2% 28.6% 31% 20% 35.1% 43.5% 55.2%
<3 (high risk) 11% 43.7% 59.9% 51.6% 74.2% 59.5% 73.1% 66% 85%
SCORE
<7 (low risk) 25% 1.6% 5.1% 11.2% 13.9% 3.6% 9.4% 22.2% 23.6%
7–15 (moderate risk) 70% 10.1% 21.2% 27.2% 36.6% 18.9% 33.5% 41.7% 52.8%
>15 (high risk) 5% 42.9% 57.1% 51.3% 73.8% 57.6% 70.2% 66.5% 83.3%
ORAI
<9 (low risk) 40% 2.4% 8.3% 14.5% 19.1% 6.1% 15.3% 26.5% 31.7%
9–17 (moderate risk) 47% 10.4% 20.1% 27.6% 36.5% 18.8% 32.4% 42.3% 52.8%
>17 (high risk) 13% 27.4% 46.1% 42.3% 60% 42.3% 59.2% 57% 75.4%
OSIRIS
>1 (low risk) 46% 1.9% 7% 14.2% 17.7% 5.1% 13.5% 25.9% 30.9%
 3 to 1 (moderate risk) 42% 10.2% 22.1% 28.9% 38.7% 19.9% 35.1% 44.5% 55.3%
<3 (high risk) 12% 35.6% 52.5% 48.3% 67.6% 51.3% 67.2% 61.3% 81.2%
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the same risk tool categories as Geusens et al.16 to
compare the performance of the various tools in a
different population, and found very similar results
for OST at the T-score 2.0 and 2.5 cut-offs.
We were unable to assess the SOFSURF index,
developed by Black et al.,13 based on age, weight,
history of fracture, and smoking status, since
smoking status was not recorded in our database.
The SCORE, ORAI, OSIRIS, and OST are vali-
dated risk indices that can help physicians and
public health representatives to focus DXA testing
on individuals at increased risk of osteoporosis. All
four risk tools performed similarly, and identified a
significant proportion of all women at low risk who
would not benefit from BMD measurements. These
indices have been studied and validated in several
different large populations, and different risk index
cut-offs have been determined for White versus
Asian populations. Each of these four risk tools was
developed using comprehensive surveys of numer-
ous potential risk factors together with statistical
analyses to identify the most important predictors of
low BMD. Good performance was achieved using
only a few risk factors, and additional risk factors did
not further improve performance. Given the con-
sistency of results across studies, it seems likely that
existing risk tools represent the best achievable
performance using self-reported risk factors, and
efforts should now be directed at using these tools
in clinical practice.
As with most studies, our study has limitations.
For example, the subjects in our sample were either
referred or came in spontaneously for osteoporosis
evaluations, and may differ in some ways from
the general population such as socioeconomic
and education levels, or the prevalence of some
conditions associated with osteoporosis (i.e. the
prevalence of smoking and alcohol consumption,29
vitamin D or calcium deficiency30,31 or long-term
corticosteroid use32). A local Belgian BMD refer-
ence range was used for calculating T-scores,
because it was felt to be representative of the
Belgium population. Compared to the US reference
data from NHANES III,34 differences for the BMD
cutoffs using the Belgian reference data were about
5% for the T-score¼2.5 cutoff. This may explain
the somewhat higher prevalence of osteoporosis in
this sample of Belgian women, compared to the
report of Geusens et al.16
The identification of low bone mass in post-
menopausal women should be of higher priority if
we are to curtail the growing tide of fractures that
are already a substantial socioeconomic problem
in developed countries. Although most physicians
and patients are aware of osteoporosis, it is only
diagnosed and appropriately treated in a small
proportion of patients, even those with prior
fractures.34,35 Measuring BMD is the best method
of identifying patients with osteoporosis to consider
for treatment, but measuring BMD in all postmeno-
pausal women is not feasible in most countries. The
OST tool performed as well in this White population
as it did in earlier studies to help target BMD
measurements to women at risk. Its high negative
predictive value allows for the safe exclusion of
healthy women, in order to allocate BMD test
resources to those most likely to benefit. ORAI,
SCORE, and OSIRIS provided similar performance
in this setting. The main advantage in using the
OST index is that it is the simplest and quickest to
calculate, and thus to use as a systematic first-line
prescreening tool in post-menopausal women.
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